Gene Therapies: Mapping the Future Growth Potential
The first gene therapy, Gendicine®, was only approved in 2003 in China; since then, the domain has evolved significantly. The ‘Gene Therapy Market (2nd Edition), 2018-2030’ report provides an extensive study on the current market landscape of gene therapies, with a prime focus on gene augmentation based therapies and oncolytic viral therapies, featuring an elaborate discussion on the future potential of this evolving market. Some of the most interesting insights from our study are presented below.
A Mushrooming Area for Researchers, Gene Therapies are Now Ready for Strong Commercial Growth
With more than 34,000 patents filed in the last five years, the gene therapy market continues to garner significant interest in the biopharmaceutical industry.
The Promising Development Pipeline Holds Significant Potential
Presently, there are 8 commercialized gene therapies and close to 300 clinical / preclinical product candidates under evaluation; AAV vectors appear to be the gene delivery vehicle of choice.
Gene Therapies are Being Evaluated Across a Wide Range of Therapeutic Areas
Although oncology continues to be the major area of focus, several candidates are being developed against metabolic, ocular and a variety of other disorders.
The Landscape is a Mix of Small Start-ups / Mid-Sized Companies and Large Enterprises
Characterized by the presence of over 60 start-ups and many mid-sized and large-sized firms, the broader landscape is spread across various geographies.
Heavy Investments from Venture Capitalists Validate the Rising Interest
The field continues to garner significant attention among venture capital investors; significant support has also come in the form of grants
Vector Manufacturing CMOs are Amongst the Key Stakeholders Driving the Market Forward
CMOs offering vector manufacturing services have become indispensable to the development of novel gene therapies and gene delivery tools
The Overall Market is Expected to Witness Rapid Growth in the Near Term
Overall, prevalent trends indicate that the market for gene therapies is poised to grow significantly as multiple late stage molecules get commercialized in the near future
In the Long-Term, This Growth Will be Well-Distributed across Multiple Regions and Vector Types
In addition to US and EU, several Asian economies are expected to benefit from the anticipated growth
To know more please click Gene Therapy Market (2nd Edition), 2018-2030 For any queries / suggestions or if you’d like to get access to the full research results, please do not hesitate to contact us at sales@rootsanalysis.com
Catalent’s Shopping List: Towards a One-Stop Cell & Gene Therapy CMO
TPD and the Rise of Kymera Therapeutics
Anti-Counterfeiting Technologies in Healthcare
About Author
Arun_Gupta
Arun is an enthusiastic professional and has been associated with Roots Analysis since the very early years. He has led multifaceted roles over the years be it business research, consulting, competitive intelligence, IT & technology, sales and marketing. He currently drives strategic thinking and execution within the sales and marketing domain. With educational background in life sciences from Thapar University and digital marketing credentials from Indian School of Business, he has led a lot of critical initiatives at the organization. His background in life sciences has been one of the key reasons for quick understanding and implementation of customized marketing strategies. During his early years, he has led multiple consulting assignments for global clients ranging from competitive landscaping, deal structuring and preparing go-to-market strategy for his clients.